Online inquiry

IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9862MR)

This product GTTS-WQ9862MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD37 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001040031.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 951
UniProt ID P11049
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ9862MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11356MR IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MEDI-551
GTTS-WQ14913MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ11937MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
GTTS-WQ6971MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ4506MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ12527MR IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA NPVPDR001
GTTS-WQ11234MR IVTScrip™ mRNA-Anti-pcrV&psl, MEDI3902(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI3902
GTTS-WQ7329MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA FPA-144
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW